Strategic Partnering

We’re on a mission to make cancer more detectable.

Pioneering molecular MRI for cancer detection

We’re developing the world’s first molecular MRI contrast agents to improve the detection of cancer using bio-safe superparamagnetic nanoparticles.

Surgical outcomes improve, treatments are more successful, and survival rates increase with early detection.

By combining high-sensitivity magnetic resonance imaging (MRI) with targeted nanoparticle technology, we aim to make the detection and management of diseases like cancer better and safer for patients.

Let’s discuss partnership opportunities

Imagion Biosystems is actively seeking strategic partners to accelerate the development of our MagSense^® product portfolio.

To connect with our team, please contact us via email at partnering@imagionbio.com

Seeking partners in all areas of our business

Imaging

We are developing proprietary imaging products.

Example Applications:

- MagSense^® tumor detection: breast, prostate, ovarian, and pancreatic
- Treatment monitoring
- Bloodpool imaging
- Detection and therapy

OEM Products

We supply nanoparticles to third parties developing biomedical products.

Example Applications:

- Magnetic Hyperthermia
- Human and animal vaccines
- Cancer screening and treatments

Research

PrecisionMRX^® nanoparticles are available to academic institutions for research purposes.

Multiple coating types available:

- Carboxylic Acid Functionalized
- Dextran-Coated
- mPEG Coated
- Oleic Acid Coated

Strategic Interests with MagSense^®

MagSense^® Collaboration

We have developed our MagSense^® portfolio of targeted molecular MRI contrast agents and are interested in co-development and commercial partnerships to advance those products.

MagSense^® Companion Dx

Virtually any targeted therapeutic addressing extracellular targets (e.g., mAb or small molecule) could also be used to target a MagSense^® Companion Dx product to accelerate clinical development and improve cost-effectiveness.
We are interested in partnering with pharma to develop MagSense^®imaging agents that would improve clinical study and treatment outcomes.

Interested in a collaboration? Inquire about potential partnerships:

“Since working with Imagion Biosystems for the last few years, we’ve been able to incorporate their iron oxide nanoparticles into our hyperthermia therapeutic platform. The consistent high quality of the iron oxide nanoparticles has allowed us to ramp up our preclinical testing and move us towards human clinical trials."